Summit Therapeutics
SMMT
97 hedge funds and large institutions have $86.3M invested in Summit Therapeutics in 2023 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 36 increasing their positions, 21 reducing their positions, and 6 closing their positions.
787% more call options, than puts
Call options by funds: $896K | Put options by funds: $101K
71% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 21
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
43% more capital invested
Capital invested by funds: $60.4M → $86.3M (+$25.9M)
4% more funds holding
Funds holding: 93 → 97 (+4)
0.09% more ownership
Funds ownership: 4.63% → 4.72% (+0.09%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.89M |
| 2 |
Morgan Stanley
New York
|
+$1.76M |
| 3 |
BlackRock
New York
|
+$1.61M |
| 4 |
State Street
Boston,
Massachusetts
|
+$390K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$362K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$5.87M |
| 2 |
SAM
Shell Asset Management
The Hague,
Netherlands
|
-$457K |
| 3 |
CL
CSS LLC
Chicago,
Illinois
|
-$286K |
| 4 |
SPIA
Steward Partners Investment Advisory
New York
|
-$103K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$68K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$168 | -90 | Closed |
|
|
AF
102
Allworth Financial
Folsom,
California
| – | -$120 | -64 | Closed |
|
|
C
103
Covestor
London,
United Kingdom
| – | -$14 | -7 | -10% |
|
SMMT Hedge Fund Activity: Q4 2023 in Review
97 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q4 2023, worth a combined $86.3M — up 43% from $60.4M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new SMMT positions and 6 closed out — a net gain of 4 holders — while 36 added to existing stakes and 21 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.89M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $5.87M sold.
- 97 institutional investors held Summit Therapeutics (SMMT) as of Q4 2023, up from 93 in Q3 2023.
- Funds reported $86.3M of Summit Therapeutics stock for Q4 2023, up 43% quarter-over-quarter.
- 10 funds opened new Summit Therapeutics positions in Q4 2023 and 6 closed out, a net change of +4 holders.
- The largest Summit Therapeutics buyer in Q4 2023 was Vanguard Group, an estimated $1.89M added.
- The largest Summit Therapeutics seller in Q4 2023 was Baker Bros. Advisors, an estimated $5.87M sold.
Based on aggregated 13F filings for Q4 2023.